The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine
by

1 Answer

Answer :

B. Prejunctional, postjunctional as well as extrajunctional in location
by

Related questions

The α 2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Description : The α 2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Last Answer : B. Prejunctional, postjunctional as well as extrajunctional in location

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Last Answer : C. Do not block any effect of injected adrenaline

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

The usual cardiovascular effect of levodopa is: A. Bradycardia due to increased vagal tone B. Rise in blood pressure due to increased noradrenaline content of adrenergic nerve endings C. Fall in blood pressure due to decrease in sympathetic tone D. Both ‘A’ and ‘B’ are correct

Description : The usual cardiovascular effect of levodopa is: A. Bradycardia due to increased vagal tone B. Rise in blood pressure due to increased noradrenaline content of adrenergic nerve endings C. Fall in blood pressure due to decrease in sympathetic tone D. Both ‘A’ and ‘B’ are correct

Last Answer : C. Fall in blood pressure due to decrease in sympathetic tone

Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Description : Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Last Answer : C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation

Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Description : Adrenaline is inactive orally because it is: A. Not absorbed from the gastrointestinal tract B. Destroyed by gastric acid C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation D. Taken up by adrenergic nerve endings of the intestinal wall, liver and lungs

Last Answer : C. Completely metabolized in the intestinal mucosa and liver before reaching systemic circulation

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The following is a selective α2 adrenoceptor antagonist: A. Prazosin B. Phentolamine C. Yohimbine D. Clonidine

Description : The following is a selective α2 adrenoceptor antagonist: A. Prazosin B. Phentolamine C. Yohimbine D. Clonidine

Last Answer : C. Yohimbine

Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Last Answer : Answer : A

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is (a) Ephedrine (b) Dopamine (c) Isoprenaline (d) Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is (a) Ephedrine (b) Dopamine (c) Isoprenaline (d) Tyramine

Last Answer : Ans: D

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Description : A sympathomimetic amine that acts almost exclusively by releasing noradrenaline from the nerve endings is: A. Ephedrine B. Dopamine C. Isoprenaline D. Tyramine

Last Answer : D. Tyramine

The following is a skeletal muscle relaxant that acts as a central α2 adrenergic agonist: A. Tizanidine B. Brimonidine C. Chlormezanone D. Quinine

Description : The following is a skeletal muscle relaxant that acts as a central α2 adrenergic agonist: A. Tizanidine B. Brimonidine C. Chlormezanone D. Quinine

Last Answer : A. Tizanidine

The following is an α2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Description : The following is an α2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Last Answer : C. Brimonidine

Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Description : Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Last Answer : D. Ocular β adrenergic blockers

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

The dopamine D2 receptor has the following feature: A. It is excitatory in nature B. It is negatively coupled to adenyl cyclase C. It is selectively blocked by bromocriptine D. It is not blocked by metoclopramide

Description : The dopamine D2 receptor has the following feature: A. It is excitatory in nature B. It is negatively coupled to adenyl cyclase C. It is selectively blocked by bromocriptine D. It is not blocked by metoclopramide

Last Answer : B. It is negatively coupled to adenyl cyclase

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

Tyramine induces release of noradrenaline from adrenergic nerve endings (a) By depolarizing the axonal membrane (b) By mobilizing Ca2+ (c) By a nonexocytotic process (d) Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings (a) By depolarizing the axonal membrane (b) By mobilizing Ca2+ (c) By a nonexocytotic process (d) Only in the presence of MAO inhibitors

Last Answer : Ans: C

Drugs that block the a receptor on effector cells at adrenergic nerve endings (a) Antagonize the effects of isoproterenol on the heart rate (b) Antagonize some of the effects of epinephrine on the blood pressure (c) Antagonize the effects of epinephrine on adenylyl cyclase (d) Cause mydriasis (e) Decreases blood glucose levels

Description : Drugs that block the a receptor on effector cells at adrenergic nerve endings (a) Antagonize the effects of isoproterenol on the heart rate (b) Antagonize some of the effects of epinephrine on ... the effects of epinephrine on adenylyl cyclase (d) Cause mydriasis (e) Decreases blood glucose levels

Last Answer : Ans: B

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

Dantrolene sodium reduces skeletal muscle tone by: A. Reducing acetylcholine release from motor nerve endings B. Suppressing spinal polysynaptic reflexes C. Inhibiting the generation of muscle action potential D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre

Description : Dantrolene sodium reduces skeletal muscle tone by: A. Reducing acetylcholine release from motor nerve endings B. Suppressing spinal polysynaptic reflexes C. Inhibiting the generation of muscle action potential D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre

Last Answer : D. Reducing Ca2+ release from sarcoplasmic reticulum in the muscle fibre

All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Description : All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Last Answer : A. Direct vasodilatation

Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Description : Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Last Answer : D. Blockade of muscarinic autoreceptors on vagal nerve endings

All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Description : All of the following contribute to the antihypertensive action of propranolol except: A. Direct vasodilatation B. Decreased renin release from kidney C. Adaptation of blood vessels to reduced cardiac output D. Less noradrenaline release from sympathetic nerve endings

Last Answer : A. Direct vasodilatation

Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Description : Initial bradycardia caused by intramuscular injection of atropine is believed to be caused by: A. Stimulation of medullary vagal centre B. Stimulation of vagal ganglia C. Blockade of M2 receptors on SA nodal cells D. Blockade of muscarinic autoreceptors on vagal nerve endings

Last Answer : D. Blockade of muscarinic autoreceptors on vagal nerve endings

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Description : What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Last Answer : C. It improves penile tumescence in men with erectile dysfunction

What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Description : What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Last Answer : C. It improves penile tumescence in men with erectile dysfunction

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

Which pressor agent acts directly as well as indirectly and produces both vasoconstriction and cardiac stimulation: A. Phenylephrine B. Methoxamine C. Noradrenaline D. Mephentermine

Description : Which pressor agent acts directly as well as indirectly and produces both vasoconstriction and cardiac stimulation: A. Phenylephrine B. Methoxamine C. Noradrenaline D. Mephentermine

Last Answer : D. Mephentermine

Which pressor agent acts directly as well as indirectly and produces both vasoconstriction and cardiac stimulation: A. Phenylephrine B. Methoxamine C. Noradrenaline D. Mephentermine

Description : Which pressor agent acts directly as well as indirectly and produces both vasoconstriction and cardiac stimulation: A. Phenylephrine B. Methoxamine C. Noradrenaline D. Mephentermine

Last Answer : D. Mephentermine

Which pressor agent acts directly as well as indirectly and produces both vasoconstriction and cardiac stimulation: A. Phenylephrine B. Methoxamine C. Noradrenaline D. Mephentermine

Description : Which pressor agent acts directly as well as indirectly and produces both vasoconstriction and cardiac stimulation: A. Phenylephrine B. Methoxamine C. Noradrenaline D. Mephentermine

Last Answer : D. Mephentermine

Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Description : Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Last Answer : A. It is less likely to cause rebound hypertension on sudden discontinuation

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Description : The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Last Answer : D. All of the above

The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Description : The cotransmitter may serve the following function/ functions: A. Regulate the release of the primary transmitter from the nerve ending B. Alter postjunctional action of the primary transmitter C. Itself act as an alternative transmitter D. All of the above

Last Answer : D. All of the above

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Description : Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Last Answer : Answer : D